B. Riley Issues Optimistic Outlook for Altimmune Earnings

Key Points

• Equities analysts at B. Riley have raised their Q3 2025 earnings per share estimate for Altimmune from ($0.32) to ($0.30), maintaining a "Buy" rating with a price target of $18.00.
• In their latest quarterly earnings report, Altimmune beat analysts' expectations by reporting an EPS of ($0.27) despite a negative net margin of over 438,000%.
• Altimmune's stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.40, with various ratings from different research institutions.

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at B. Riley upped their Q3 2025 earnings estimates for Altimmune in a report released on Wednesday, August 13th. B. Riley analyst M. Mamtani now forecasts that the company will earn ($0.30) per share for the quarter, up from their prior estimate of ($0.32). B. Riley has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Altimmune's current full-year earnings is ($1.35) per share. B. Riley also issued estimates for Altimmune's Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($1.24) EPS.

Several other equities analysts also recently issued reports on ALT. The Goldman Sachs Group raised shares of Altimmune to a "strong sell" rating in a report on Thursday, July 10th. William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday, June 27th. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research report on Wednesday, August 13th. Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, JMP Securities reduced their target price on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating for the company in a research report on Thursday, July 10th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Altimmune has a consensus rating of "Moderate Buy" and a consensus price target of $17.40.

Altimmune Price Performance

ALT traded up $0.01 during midday trading on Friday, hitting $3.63. 2,218,988 shares of the company traded hands, compared to its average volume of 3,770,638. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $320.37 million, a price-to-earnings ratio of -3.08 and a beta of -0.01. Altimmune has a 52-week low of $2.90 and a 52-week high of $11.16. The business has a 50 day simple moving average of $4.64 and a two-hundred day simple moving average of $5.23.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently made changes to their positions in ALT. LPL Financial LLC increased its position in shares of Altimmune by 15.2% during the fourth quarter. LPL Financial LLC now owns 58,173 shares of the company's stock valued at $419,000 after acquiring an additional 7,693 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Altimmune by 2.0% during the fourth quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company's stock valued at $742,000 after acquiring an additional 2,028 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Altimmune by 69.3% during the fourth quarter. Wells Fargo & Company MN now owns 215,538 shares of the company's stock valued at $1,554,000 after acquiring an additional 88,209 shares during the last quarter. Invesco Ltd. increased its position in shares of Altimmune by 679.2% during the fourth quarter. Invesco Ltd. now owns 247,086 shares of the company's stock valued at $1,781,000 after acquiring an additional 215,375 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Altimmune during the fourth quarter valued at about $88,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.